JANSSEN LETTER TO P&T COMMITTEE SEEKING UNRESTRICTED STATUS FOR SPORANOX MISREPRESENTS CURE RATES, DDMAC SAYS; COMPARISON TO LAMISIL "UNSUBSTANTIATED"
A letter that Janssen reps allegedly disseminated to a Pharmacy and Therapeutics committee requesting "unrestricted" status for Sporanox (itraconazole capsules) falsely claims clinical cure rates of 70% to 84% in the treatment of onychomycosis, FDA's Division of Drug Marketing, Advertising and Communications states in a March 27 letter to the company.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth